Humanigen Inc. (HGEN)

19.59 +0.82 (4.37%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Form 8-K HUMANIGEN, INC For: Jan 21 January 22, 2021 10:42 AM - SEC Filing Humanigen Inc. (HGEN) Announces Addition of BARDA and Expansion of CRADA with U.S. Government to Develop Lenzilumab for COVID-19 January 22, 2021 7:02 AM - StreetInsider Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19 January 22, 2021 7:00 AM - BizWire Form 4 HUMANIGEN, INC For: Jan 19 Filed by: NOMIS BAY LTD. January 21, 2021 9:01 PM - SEC Filing Form 4 HUMANIGEN, INC For: Jan 14 Filed by: NOMIS BAY LTD. January 19, 2021 6:36 PM - SEC Filing Form 8-K HUMANIGEN, INC For: Jan 19 January 19, 2021 5:25 PM - SEC Filing Form 8-K HUMANIGEN, INC For: Jan 09 January 14, 2021 4:31 PM - SEC Filing Form 4 HUMANIGEN, INC For: Jan 11 Filed by: NOMIS BAY LTD. January 13, 2021 5:23 PM - SEC Filing Humanigen (HGEN) Announces Partnership to Commercialize Nasal Spray that Fights COVID Cytokine Storm, Expects EUA - Roth Capital January 11, 2021 6:24 AM - StreetInsider Form 8-K HUMANIGEN, INC For: Jan 11 January 11, 2021 6:08 AM - SEC Filing Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 January 10, 2021 8:00 AM - BizWire Form 8-K HUMANIGEN, INC For: Jan 01 January 7, 2021 4:30 PM - SEC Filing Humanigen to Present at Multiple Upcoming Investor Conferences January 5, 2021 4:30 PM - BizWire Form 424B5 HUMANIGEN, INC December 31, 2020 4:47 PM - SEC Filing Form 8-K HUMANIGEN, INC For: Dec 31 December 31, 2020 4:38 PM - SEC Filing Form 4 HUMANIGEN, INC For: Dec 28 Filed by: NOMIS BAY LTD. December 31, 2020 4:31 PM - SEC Filing Form 4/A HUMANIGEN, INC For: Dec 22 Filed by: NOMIS BAY LTD. December 28, 2020 5:19 PM - SEC Filing Form 4 HUMANIGEN, INC For: Dec 23 Filed by: NOMIS BAY LTD. December 28, 2020 5:18 PM - SEC Filing Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy December 28, 2020 7:00 AM - BizWire Form 4 HUMANIGEN, INC For: Dec 22 Filed by: NOMIS BAY LTD. December 23, 2020 4:07 PM - SEC Filing Form 4 HUMANIGEN, INC For: Dec 18 Filed by: NOMIS BAY LTD. December 23, 2020 9:18 AM - SEC Filing National Securities Starts Humanigen (HGEN) at Buy December 23, 2020 5:03 AM - StreetInsider UPDATE: Jefferies Starts Humanigen (HGEN) at Buy December 22, 2020 4:09 AM - StreetInsider Humanigen to Present at J.P. Morgan Healthcare Conference December 17, 2020 8:00 AM - BizWire Humanigen Inc. (HGEN) Reports Complete Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme December 17, 2020 7:06 AM - StreetInsider Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme December 17, 2020 7:00 AM - BizWire Humanigen to Present at Upcoming Investor Conferences December 14, 2020 8:00 AM - BizWire Form 424B3 HUMANIGEN, INC November 30, 2020 5:01 PM - SEC Filing Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans November 23, 2020 4:05 PM - BizWire Form EFFECT HUMANIGEN, INC November 20, 2020 6:04 AM - SEC Filing Form POS AM HUMANIGEN, INC November 13, 2020 4:22 PM - SEC Filing Form 424B3 HUMANIGEN, INC November 12, 2020 4:17 PM - SEC Filing Form 8-K HUMANIGEN, INC For: Nov 11 November 12, 2020 6:07 AM - SEC Filing Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results November 11, 2020 7:00 AM - BizWire Form 10-Q HUMANIGEN, INC For: Sep 30 November 10, 2020 4:54 PM - SEC Filing Humanigen (HGEN) PT Raised to $34 at H.C. Wainwright November 6, 2020 10:23 AM - StreetInsider Form 424B3 HUMANIGEN, INC November 6, 2020 9:14 AM - SEC Filing Form 8-K HUMANIGEN, INC For: Nov 05 November 6, 2020 9:06 AM - SEC Filing Humanigen (HGEN) Announces Positive Interim Phase 3 Data of Lenzilumab in Patients Hospitalized with COVID-19 November 6, 2020 7:06 AM - StreetInsider Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19 November 6, 2020 7:00 AM - BizWire Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19 November 6, 2020 7:00 AM - BizWire Form 424B3 HUMANIGEN, INC November 4, 2020 5:01 PM - SEC Filing Form 8-K HUMANIGEN, INC For: Oct 29 November 4, 2020 4:45 PM - SEC Filing Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting November 4, 2020 4:05 PM - BizWire Humanigen Inc. (HGEN) Executes Licensing Agreement for Lenzilumab in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines November 3, 2020 7:36 AM - StreetInsider Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines November 3, 2020 7:30 AM - BizWire Humanigen Inc. (HGEN) Reports First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19 October 30, 2020 2:11 PM - StreetInsider Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19 October 30, 2020 2:05 PM - BizWire Humanigen Inc. (HGEN) Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19 October 29, 2020 7:56 AM - StreetInsider Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab™ for COVID-19 October 29, 2020 7:00 AM - BizWire Humanigen to Present at Upcoming Investor Conferences October 27, 2020 4:01 PM - BizWire Full Article List